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Abstract Excessive sweating is a well-known side eﬀect
of a selective serotonin reuptake inhibitor treatment, but
little is known about the impact of sweating on treat-
ment discontinuation or the general quality of life of
patients. In this case report, we present a patient suf-
fering from excessive sweating induced by escitalopram.
When mirtazapine was administered as an additional
treatment, a dose-dependent reduction of drug-induced
excessive sweating was observed. Taking into account
the particular serotonin antagonistic properties of
mirtazapine, its eventual inﬂuence on the regulation of
body temperature and diaphoresis in the central nervous
system is discussed.
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Introduction
Over the past two decades, selective serotonin reuptake
inhibitors (SSRIs) have become the gold standard for
the treatment of the majority of mood and anxiety dis-
orders. Although their overall tolerability is generally
satisfactory, SSRIs are also known to cause a large
number of side eﬀects, with gastro-intestinal and sexual
disturbances being particularly emphasized in recent
publications. Excessive sweating is another well-known
side eﬀect, which occurs in about 10% of patients
receiving SSRIs [1], but little is known about the impact
of sweating on treatment discontinuation or the general
quality of life of patients. There are several reports from
clinicians describing management of drug-induced
excessive sweating in patients with the use of drugs such
as benztropine [2, 3], clonidine [4], and cyproheptadine
[5]. In this report, we present an observation made in the
treatment of sweating with mirtazapine, which is known
to have particular serotonin (5-HT) antagonistic prop-
erties.
Case report
Mr A, a 63-year-old man, has been known for an
aﬀective bipolar disorder type I since the age of 45 years.
He has mainly been suﬀering from recurrent and per-
sistent depressive episodes. Over the last 10 years, many
diﬀerent pharmacological treatments were tried by both
his psychiatrist and his general practitioner, none of
which was eﬃcacious in durably stabilizing his mood.
Finally, the patient was referred to our specialized out-
patient clinic in order to re-evaluate his treatment. The
patient reported having received the following antide-
pressant drugs over the past 10 years: trazodone
(200 mg/day), ﬂuoxetine (40 mg/day), moclobemide
(600 mg/day), trimipramine (50 mg/day), mianserin
(30 mg/day), venlafaxine (37.5 mg/day), and escitalop-
ram (5 mg/day). He had subsequently been treated with
mood stabilizers, including lithium sulfate (1,320 mg/
day) and carbamazepine (400 mg/day), and he was
taking valproic acid (2,000 mg/day) at the moment of
his transfer to our clinic. Because of suﬀering from
permanent and distressing anxious tension as well as
chronic insomnia, he also received benzodiazepines (lo-
razepam 7.5 mg/day).
In addition, as he was suﬀering from arterial hypo-
tension, hyperuricemia, chronic gastritis, hypercholes-
terolemia, coronary heart disease, and essential tremor,
he was concomitantly treated with simvastatine (20 mg/
day), aspirin (100 mg/day), pantoprazol (40 mg/day),
allopurinol (150 mg/day), propanolol (160 mg/day), and
nitroglycerine (0.8 mg occasionally).
On this medication, the patient experienced multiple
drug-related side eﬀects, including persistent gastro-
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intestinal disturbances, cognitive impairment, aggrava-
tion of his tremor, and excessive sweating. These side
eﬀects, as well as the recurrent depressive episodes, re-
sulted in a considerable reduction of his quality of life.
On arrival at our clinic, the antidepressant treatment
consisted of escitalopram 5 mg/day. The dose was pro-
gressively increased to 30 mg/day. After 1 month, the
patient experienced a satisfactory improvement of his
mood as well as of his general anxiety level and therefore
wished to continue this antidepressant agent for a longer
period. However, on this dose increase the pre-existing
sweating worsened considerably. In both winter and
summer time, he carried a towel around his neck to dry
his face and reported changing his clothes two or three
times per day.
Considering the serotonergic proﬁle of escitalopram,
and the 5-HT2 and 5-HT3 receptor blocking properties
of mirtazapine [6], the latter drug was introduced at
15 mg/day, as an additional treatment, to possibly
modulate 5-HT-dependent thermoregulation and
sweating. About 2 weeks later, the excessive sweating
was considerably reduced and the patient reported a
noticeable improvement of his quality of life. The pa-
tient tolerated his new treatment combination well and,
progressively, the dose of mirtazapine was increased to
60 mg/day. This dose increase resulted in a complete
remission of the excessive sweating, and 10 months later
the improvement persisted.
Discussion
To our knowledge, this is the ﬁrst observation of mirt-
azapine as an eﬀective ‘‘antidote’’ treatment for SSRI-
induced sweating. A dose-dependent eﬀect on excessive
sweating was observed in the range between 15 mg/day
and 60 mg/day. The mirtazapine prescription was also
well tolerated in conjunction with a large number of
other drugs administered simultaneously.
Little is known about the regulation of body tem-
perature and diaphoresis in the central nervous system.
However, there is evidence that activation of central 5-
HT2A receptors plays an important role in the elevation
of body temperature [7]. As mirtazapine possesses 5-HT2
blocking properties, the observed therapeutic eﬀect on
sweating may possibly be associated with a modulation
of serotonergic thermoregulation.
We are fully aware of the many potential drug
interactions that may have inﬂuenced the observed ef-
fects. For this reason, the extrapolation of a general
‘‘antidote’’ eﬀect of mirtazapine for SSRI-induced
sweating is limited and there is clearly a need for further
investigation involving controlled clinical trials. How-
ever, we hope that the present case report may con-
tribute to understanding the mechanisms underlying
SSRI-induced sweating, suggesting a critical role of the
5-HT2 receptor.
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